Amgen Says Delaware Jury Upholds Co's Patents On Repatha
February 25 2019 - 6:22PM
Dow Jones News
By Stephen Nakrosis
A Delaware jury delivered a verdict upholding two of Amgen
Inc.'s (AMGN) patents related to PCSK9 antibodies, the company said
Monday.
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) had
contended that Amgen's patent claims to the antibodies was overly
broad, and the companies said they will file post-motion decisions
and, if necessary, appeal the decision.
"Today's decision protects intellectual property which is
essential to innovators who are bringing forward new medicines for
patients with serious diseases," said Robert A. Bradway, chairman
and chief executive officer at Amgen. "We are thankful that the
jury weighed the evidence carefully and recognized the validity of
Amgen's patents."
Amgen also said the European Patent Office and the Japanese
Patent Office rejected challenges to the validity of Amgen's
patents brought by the two companies.
"We are disappointed in today's verdict," said Karen Linehan,
executive vice president and general counsel, Sanofi. "It is our
longstanding belief that all of Amgen's asserted U.S. patent claims
are invalid and we believe the law and the facts support our
positions."
Regeneron and Sanofi said they plan to file post-trial motions
over the next few months, in an effort to overturn the verdict and
request a new trial. The two companies also said if necessary they
will file an appeal with the U.S. Court of Appeals for the Federal
Circuit.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 25, 2019 18:07 ET (23:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Sep 2023 to Sep 2024